University of Oulu

URPILAINEN, E., ARIMA, R., KARIHTALA, P., PUISTOLA, U., & AHTIKOSKI, A. (2021). Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes. Anticancer Research, 41(2), 821–828. https://doi.org/10.21873/anticanres.14834

Metformin associates with aggressive features of endometrial cancer in women with type 2 diabetes

Saved in:
Author: Urpilainen, Elina1; Arima, Reetta2; Karihtala, Peeter3;
Organizations: 1Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
2Department of Obstetrics and Gynaecology, Central Finland Central Hospital, Jyväskylä, Finland
3Department of Oncology, University of Helsinki and Helsinki University Comprehensive Cancer Center, Helsinki, Finland
4Department of Pathology, Cancer and Translational Medicine Research Unit, Oulu University Hospital and University of Oulu, Oulu, Finland
Format: article
Version: published version
Access: embargoed
Persistent link: http://urn.fi/urn:nbn:fi-fe202102043724
Language: English
Published: International Institute of Anticancer Research, 2021
Publish Date: 2021-05-30
Description:

Abstract

Background/Aim: Preclinical studies on metformin use and endometrial cancer have been promising but epidemiological studies have reported variable results. This study aimed to assess if metformin use is associated with endometrial cancer aggressiveness and survival in women with type 2 diabetes (T2D).

Patients and methods: This retrospective hospital-based cohort consisted of women with T2D who were treated for endometrial cancer at the Oulu University Hospital, Finland, between 2007 and 2014.

Results: The sample size was 121 patients: 58 metformin users and 63 metformin non-users. Intriguingly, type 2 histology, deep myometrial invasion and the presence of lymphovascular invasion were more common in the metformin user group. However, metformin use showed no association with overall survival and progression-free survival.

Conclusion: Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D.

see all

Series: Anticancer research
ISSN: 0250-7005
ISSN-E: 1791-7530
ISSN-L: 0250-7005
Issue: 2
Pages: 821 - 828
DOI: 10.21873/anticanres.14834
OADOI: https://oadoi.org/10.21873/anticanres.14834
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
3123 Gynaecology and paediatrics
Subjects:
Funding: This study was funded by grants from the Jane and Aatos Erkko Foundation (T59127) and the Finnish Government Research Funds (K77729) granted to the University Hospital of Oulu. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Copyright information: Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. Published in this repository with the kind permission of the publisher.